This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Fratte, S. D. Articles by Domenici, E. Search for Related Content PubMed PubMed Citation Articles by Fratte, S. D. Articles by Domenici, E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB DIMETHYL SULFOXIDE Social Bookmarking                         What's this?

Development of a High-Throughput Scintillation Proximity Assay for the Identification of C-Domain Translational Initiation Factor 2 Inhibitors

GlaxoSmithKline Medicines Research Center, Verona, Italy

Chiara Piubelli

GlaxoSmithKline Medicines Research Center, Verona, Italy, Department of Agricultural and Industrial Biotechnology, University of Verona, Verona, Italy

Enrico Domenici

GlaxoSmithKline Medicines Research Center, Verona, Italy

Translational initiation factor 2 (IF2) is the largest of the 3 factors required for translation initiation in prokaryotes and has been shown to be essential in Escherichia coli. It stimulates the binding of fMet-tRNA_f^Met to the 30S ribosomal subunit in the presence of GTP. The selectivity is achieved through specific recognition of the tRNA_f^Met blocked -amino group. IF2 is composed of 3 structural domains: N-domain, whose function is not known; G-domain, which contains the GTP/GDP binding site and the GTPase catalytic center; and C-domain, which recognizes and binds fMet-tRNA_f^Met. Its activity is strictly bacteria specific and highly conserved among prokaryotes. So far, antibiotics targeting IF2 function are not known, and this makes it an ideal target for new drugs with mechanisms of resistance not yet developed. A few assays have been developed in the past, which allow the detection of IF2 activity either directly or indirectly. In both instances, the assays are based on radioactive detection and do not allow for high throughput because of the need for separation or solvent extraction steps. The authors describe a novel biochemical assay for IF2 that exploits the molecular recognition of fMet-tRNA_f^Met by the C-domain. The assay is based on the incubation of biotinyl-IF2 with fMet-tRNA_f^Met and the subsequent capture of the radiolabeled complex by streptavidin-coated beads, exploiting the scintillation proximity assay (SPA) technology. The assay has been designed in an automatable, homogeneous, miniaturized fashion suitable for high-throughput screening and is rapid, sensitive, and robust to dimethyl sulfoxide (DMSO) up to 10% v/v. The assay, used to screen a limited chemical collection of about 5000 compounds and a subset of compounds originated by a 2-D substructural search, has shown to be able to detect potential IF2 inhibitors.

Journal of Biomolecular Screening, Vol. 7, No. 6, 541-546 (2002)
DOI: 10.1177/1087057102238628


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Sun, Y. Newbatt, L. Douglas, P. Workman, W. Aherne, and S. Linardopoulos High-Throughput Screening Assay for Identification of Small Molecule Inhibitors of Aurora2/STK15 Kinase J Biomol Screen, August 1, 2004; 9(5): 391 - 397. [Abstract] [PDF]